Literature DB >> 28777661

Minimal Risk in Pediatric Research: A Philosophical Review and Reconsideration.

John Rossi1, Robert M Nelson2.   

Abstract

Despite more than thirty years of debate, disagreement persists among research ethicists about the most appropriate way to interpret the U.S. regulations on pediatric research, specifically the categories of "minimal risk" and a "minor increase over minimal risk." Focusing primarily on the definition of "minimal risk," we argue in this article that the continued debate about the pediatric risk categories is at least partly because their conceptual status is seldom considered directly. Once this is done, it becomes clear that the most popular strategy for interpreting "minimal risk"-defining it as a specific set of risks-is indefensible and, from a pragmatic perspective, unlikely to resolve disagreement. Primarily this is because judgments about minimal risk are both normative and heavily intuitive in nature and thus cannot easily be captured by reductions to a given set of risks. We suggest instead that a more defensible approach to evaluating risk should incorporate room for reflection and deliberation. This dispositional, deliberative framework can nonetheless accommodate a number of intellectual resources for reducing reliance on sheer intuition and improving the quality of risk evaluations.

Entities:  

Keywords:  Ethics and public policy; history of research ethics; human subjects ethics; human subjects regulation and oversight; pediatric research ethics; research ethics

Mesh:

Year:  2017        PMID: 28777661      PMCID: PMC5618101          DOI: 10.1080/08989621.2017.1363650

Source DB:  PubMed          Journal:  Account Res        ISSN: 0898-9621            Impact factor:   2.622


  29 in total

1.  Evaluating the risks of clinical research.

Authors:  Annette Rid; Ezekiel J Emanuel; David Wendler
Journal:  JAMA       Date:  2010-10-06       Impact factor: 56.272

2.  Minimal risk in pediatric research.

Authors:  David Wendler; Sumeeta Varma
Journal:  J Pediatr       Date:  2006-12       Impact factor: 4.406

3.  Determining risk in pediatric research with no prospect of direct benefit: time for a national consensus on the interpretation of federal regulations.

Authors:  Celia B Fisher; Susan Z Kornetsky; Ernest D Prentice
Journal:  Am J Bioeth       Date:  2007-03       Impact factor: 11.229

4.  A relative standard for minimal risk is unnecessary and potentially harmful to children: lessons from the Phambili trial.

Authors:  Robert M Nelson
Journal:  Am J Bioeth       Date:  2011-06       Impact factor: 11.229

5.  A proposal and prototype for a Research Risk Repository to improve the protection of research participants.

Authors:  Annette Rid; David Wendler
Journal:  Clin Trials       Date:  2011-08-22       Impact factor: 2.486

6.  How best to define the concept of minimal risk.

Authors:  Anna E Westra; Jan M Wit; Rám N Sukhai; Inez D de Beaufort
Journal:  J Pediatr       Date:  2011-07-20       Impact factor: 4.406

7.  Nontherapeutic research with children: the Ramsey versus McCormick debate.

Authors:  Albert R Jonsen
Journal:  J Pediatr       Date:  2006-07       Impact factor: 4.406

8.  In loco parentis. Minimal risk as an ethical threshold for research upon children.

Authors:  B Freedman; A Fuks; C Weijer
Journal:  Hastings Cent Rep       Date:  1993 Mar-Apr       Impact factor: 2.683

9.  The Role of Intuition in Risk/Benefit Decision-Making in Human Subjects Research.

Authors:  David B Resnik
Journal:  Account Res       Date:  2016-06-13       Impact factor: 2.622

10.  How do institutional review boards apply the federal risk and benefit standards for pediatric research?

Authors:  Seema Shah; Amy Whittle; Benjamin Wilfond; Gary Gensler; David Wendler
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

View more
  1 in total

1.  A CTSA One Health Alliance guidance on institutional review of veterinary clinical studies.

Authors:  A O'Kell; H Borghese; S A Moore; R Garabed; H O'Meara; P Baneux
Journal:  BMC Vet Res       Date:  2021-02-17       Impact factor: 2.741

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.